Home LiteratureArticle Details
PMID: 22264257 Published · epublish English Journal Article Review

Epithelial-mesenchymal transition, cancer stem cells and treatment resistance.

Breast cancer research : BCR ·Vol. 14 ·No. 1 ·2012-01-19 ·Pages 202

Dave B, Mittal V, Tan NM, Chang JC

Abstract

Breast cancer relapse, in a large number of patients, after initial response to standard of care therapy warrants development of novel therapies against recurrent and metastatic cancer. Cancer stem cells (CSCs), present in breast tumors while being intrinsically resistant to conventional therapy, have the ability to self renew and cause tumor recurrence. The residual tumors after therapy, with dramatic enrichment of the CSCs, have all the hallmarks of epithelial- mesenchymal transition (EMT). This review will focus on the link between EMT, CSCs and treatment resistance, since a better understanding of these interactions will allow us to effectively target the residual population after therapy.

MeSH Terms
Animals Breast Neoplasms/drug therapy,pathology Cell Transformation, Neoplastic/pathology Drug Resistance, Neoplasm Epithelial-Mesenchymal Transition Female Humans Neoplastic Stem Cells/drug effects,pathology,physiology
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Dave Bhuvanesh
Methodist Hospital Cancer Center, 6550 Fannin Street SM383, Houston, TX 77030, USA.
Mittal Vivek
Tan Nicholas M
Chang Jenny C
References (43)
43 references, click to expand
  1. EMT tumorigenesis in the mouse mammary gland.
    Lab Invest. 2007 Dec;87(12):1218-26 PMID: 17922020
  2. Coordinating early kidney development: lessons from gene targeting.
    Nat Rev Genet. 2002 Jul;3(7):533-43 PMID: 12094231
  3. Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia.
    J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):75-86 PMID: 15886888
  4. Vimentin and epithelial-mesenchymal transition in human breast cancer--observations in vitro and in vivo.
    Cells Tissues Organs. 2007;185(1-3):191-203 PMID: 17587825
  5. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis.
    Hum Pathol. 2005 Jan;36(1):44-50 PMID: 15712181
  6. Epithelial-mesenchymal transitions in tumour progression.
    Nat Rev Cancer. 2002 Jun;2(6):442-54 PMID: 12189386
  7. Mesenchymal to epithelial transition in development and disease.
    Cells Tissues Organs. 2007;185(1-3):7-19 PMID: 17587803
  8. Epithelial-mesenchymal transition and its implications for fibrosis.
    J Clin Invest. 2003 Dec;112(12):1776-84 PMID: 14679171
  9. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients.
    J Clin Oncol. 2005 Feb 20;23(6):1169-77 PMID: 15718313
  10. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes.
    Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54 PMID: 20713713
  11. The epithelial-mesenchymal transition generates cells with properties of stem cells.
    Cell. 2008 May 16;133(4):704-15 PMID: 18485877
  12. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers.
    Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10069-74 PMID: 17537911
  13. Mouse models for human epithelial disease: novel insights and new horizons.
    Exp Physiol. 2009 Feb;94(2):169-70 PMID: 19144746
  14. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis.
    Science. 2008 Jan 11;319(5860):195-8 PMID: 18187653
  15. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney.
    J Biol Chem. 2005 Mar 4;280(9):8094-100 PMID: 15591043
  16. An overview of epithelio-mesenchymal transformation.
    Acta Anat (Basel). 1995;154(1):8-20 PMID: 8714286
  17. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.
    Cancer Res. 2008 Feb 15;68(4):989-97 PMID: 18281472
  18. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
    J Natl Cancer Inst. 2008 May 7;100(9):672-9 PMID: 18445819
  19. Expression profiling of epithelial plasticity in tumor progression.
    Oncogene. 2003 Oct 16;22(46):7155-69 PMID: 14562044
  20. Prospective identification of tumorigenic breast cancer cells.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 PMID: 12629218
  21. The role of epithelial-mesenchymal transition in cancer pathology.
    Pathology. 2007 Jun;39(3):305-18 PMID: 17558857
  22. Versican expression in pharyngeal squamous cell carcinoma: an immunohistochemical study.
    J Clin Pathol. 2004 Jul;57(7):735-9 PMID: 15220367
  23. Mechanisms of TGF-beta signaling from cell membrane to the nucleus.
    Cell. 2003 Jun 13;113(6):685-700 PMID: 12809600
  24. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited.
    Nat Rev Cancer. 2003 Jun;3(6):453-8 PMID: 12778135
  25. Versican mediates mesenchymal-epithelial transition.
    Mol Biol Cell. 2006 Apr;17(4):2009-20 PMID: 16452631
  26. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.
    Cell Stem Cell. 2007 Nov;1(5):555-67 PMID: 18371393
  27. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells.
    Cell. 2009 Aug 7;138(3):592-603 PMID: 19665978
  28. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.
    Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5 PMID: 19666588
  29. Cancer stem cells: are we missing the target?
    J Natl Cancer Inst. 2004 Apr 21;96(8):583-5 PMID: 15100335
  30. Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression.
    J Cell Physiol. 2007 Nov;213(2):374-83 PMID: 17680632
  31. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer.
    J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):253-60 PMID: 20354771
  32. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.
    Nature. 2005 Dec 8;438(7069):820-7 PMID: 16341007
  33. The epithelial-mesenchymal transition: new insights in signaling, development, and disease.
    J Cell Biol. 2006 Mar 27;172(7):973-81 PMID: 16567498
  34. High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma.
    J Clin Pathol. 2007 Mar;60(3):267-72 PMID: 16731595
  35. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
    Cancer Res. 2009 May 15;69(10):4116-24 PMID: 19435916
  36. Direct evidence for epithelial-mesenchymal transitions in breast cancer.
    Cancer Res. 2008 Feb 1;68(3):937-45 PMID: 18245497
  37. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.
    Nat Rev Cancer. 2009 Apr;9(4):265-73 PMID: 19262571
  38. Effect of screening and adjuvant therapy on mortality from breast cancer.
    N Engl J Med. 2005 Oct 27;353(17):1784-92 PMID: 16251534
  39. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer.
    Clin Cancer Res. 2002 Apr;8(4):1054-60 PMID: 11948113
  40. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.
    Genome Biol. 2007;8(5):R76 PMID: 17493263
  41. Prognostic significance of stromal versican expression in human endometrial cancer.
    Ann Oncol. 2007 Feb;18(2):269-74 PMID: 17065588
  42. Cancer metastasis: building a framework.
    Cell. 2006 Nov 17;127(4):679-95 PMID: 17110329
  43. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer.
    Clin Cancer Res. 2004 Apr 1;10(7):2491-8 PMID: 15073129
Article Info
Journal
Breast cancer research : BCR
Abbr.
Breast Cancer Res
ISSN
1465-542X
DOI
10.1186/bcr2938
Published
2012-01-19
Epub
2012-00-19
Pages
202
Language
English
Region
England
NLM ID
100927353
PMCID
PMC3496111
Subset
IM
External Links
PubMed source DOI: 10.1186/bcr2938 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2